Compare Abeona Therapeutics Inc (ABEO) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs JPMorgan Chase & Co — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while JPMorgan Chase & Co trades at $331.83 (market cap $908.94B). The key difference: JPMorgan Chase & Co is far larger — about 2434.7× Abeona Therapeutics Inc's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | JPM | |
|---|---|---|
Market Cap | $373.32M | $908.94B |
Sector | Health | Financials |
52-Week High | $7.23 | $339.22 |
52-Week Low | $4.17 | $282.78 |
Enterprise Value | $228.22M | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JPMorgan Chase (JPM) trades at $331.81, down 1.75% over the past day, with a bullish technical outlook and strong analyst consensus. The stock shows robust fundamentals, including a 31.61% net income margin and 17.03% ROE, supported by recent earnings beats. Revenue grew to $181.85B in 2025, though net income dipped slightly. Technical indicators signal bullish momentum, with moving averages supporting an uptrend and key resistance near $341.
The outlook for JPM remains positive, driven by solid profitability and Wall Street's moderate buy rating. Risks include geopolitical tensions and cybersecurity threats, but institutional buying and a $360.38 price target suggest upside potential. Investors should monitor Q2 2026 earnings for confirmation of growth trends amid volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
